Oculis Holding AG (OCS)

NGM – Real Time Price. Currency in USD

30.41

-2.24 (-6.86%)

At close: May 12, 2026, 4:00 PM EDT

30.45

+0.04 (0.13%)

Pre-market: May 13, 2026, 7:13 AM EDT

07.05.2026

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) regarding PIONEER-1, the first registrational trial within the PIONEER Program evaluating Privosegtor for the treatment of optic neuritis (ON). This formal FDA agreement confirms the design and planned analysis of the PIONEER-1 study are adequate to address the objectives necessary to support a future NDA submission, subject to a successful trial outcome and FDA review of the complete submission.

05.05.2026

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) management Oculis is on track to report topline results in June 2026 from DIAMOND Phase 3 registrational trials with OCS-01, which aims to be the first eye drop therapy for DME ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announces that the latest findings of the DME AWARE Delphi study were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. DME affects mainly a working-age population and is typically diagnosed at an average age of 52 years.1, 2 One year following diagnosis, 60% of patients are not treated2a while we know that delaying treatment is not beneficial for patients as it represents a missed opportunity to fully regain vision.

01.05.2026

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

LITE's fiscal Q3 outlook is likely to have pointed to surging AI-driven demand and strong revenue growth, but premium valuation raises the key question for investors.

01.05.2026

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

ZUG, Switzerland, May 01, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it will be highlighting the transformative potential of its late-stage pipeline, recent development milestones achieved and key areas of unmet medical needs at the Eyecelerator and Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting.

21.04.2026

Oculis Publishes Invitation to the Annual General Meeting

ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 6:00 a.m. EDT / 10:00 a.m. GMT / 12:00 p.m. CEST.

21.04.2026

Oculis Publishes Invitation to the Annual General Meeting

20.04.2026

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced completion of the final patient visit in the OCS-01 Phase 3 DIAMOND program in diabetic macular edema (DME). Oculis expects to report topline results in June 2026.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

05.05.2026

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

21.04.2026

Oculis Publishes Invitation to the Annual General Meeting

21.04.2026

Oculis Holding AG (OCS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Oculis Holding AG (OCS)

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Videos

No Data

Press releases

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Videos

No Data

Press releases

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting

Search stocks

Oculis Holding AG (OCS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Oculis Holding AG (OCS)

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Videos

No Data

Press releases

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Lumentum Q3 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Videos

No Data

Press releases

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Oculis Publishes Invitation to the Annual General Meeting

Oculis Publishes Invitation to the Annual General Meeting